CT LAB INC has a total of 16 patent applications. Its first patent ever was published in 1965. It filed its patents most often in China, Taiwan and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and packaging and shipping are NEUROTECH PHARMACEUTICALS CO LTD, MACGREGOR ALEXANDER and DS BIOPHARMA LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 4 | |
#2 | Taiwan | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | United States | 2 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Packaging and shipping |
# | Name | Total Patents |
---|---|---|
#1 | Shane Guang-Tzuu | 7 |
#2 | Lee Huai-Cheng | 6 |
#3 | Wang Hsi-Chieh | 4 |
#4 | Lin Rongjin | 4 |
#5 | Din Chuen-Lin | 3 |
#6 | Lin Rong Jin | 3 |
#7 | Chen Chien-Fen | 3 |
#8 | Lee Huai Cheng | 2 |
#9 | Yeh Yu-Yin | 2 |
#10 | Hsu Jui-Pao | 2 |
Publication | Filing date | Title |
---|---|---|
WO2012129759A1 | Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
TW201116827A | Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine dl receptor | |
TW201110970A | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
CN1883481A | Composition of leukotrienes antagonist oral liquid | |
TW200631581A | A pharmaceutical composition for antitussive | |
TW200624119A | An oral liquid pharmaceutical composition of leukotriene antagonists | |
US3338447A | Quick closing stopper |